CHRS
Price
$1.17
Change
-$0.05 (-4.13%)
Updated
Nov 19, 04:59 PM (EDT)
Capitalization
146.25M
118 days until earnings call
Intraday BUY SELL Signals
RXRX
Price
$4.04
Change
-$0.13 (-3.12%)
Updated
Nov 19, 04:59 PM (EDT)
Capitalization
2.1B
105 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

CHRS vs RXRX

Header iconCHRS vs RXRX Comparison
Open Charts CHRS vs RXRXBanner chart's image
Coherus Oncology
Price$1.17
Change-$0.05 (-4.13%)
Volume$5.03K
Capitalization146.25M
Recursion Pharmaceuticals
Price$4.04
Change-$0.13 (-3.12%)
Volume$202.34K
Capitalization2.1B
CHRS vs RXRX Comparison Chart in %
CHRS
Daily Signal:
Gain/Loss:
RXRX
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
CHRS vs. RXRX commentary
Nov 20, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CHRS is a Hold and RXRX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 20, 2025
Stock price -- (CHRS: $1.21 vs. RXRX: $4.16)
Brand notoriety: CHRS and RXRX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CHRS: 97% vs. RXRX: 51%
Market capitalization -- CHRS: $146.25M vs. RXRX: $2.1B
CHRS [@Biotechnology] is valued at $146.25M. RXRX’s [@Biotechnology] market capitalization is $2.1B. The market cap for tickers in the [@Biotechnology] industry ranges from $106.82B to $0. The average market capitalization across the [@Biotechnology] industry is $2.15B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CHRS’s FA Score shows that 2 FA rating(s) are green whileRXRX’s FA Score has 1 green FA rating(s).

  • CHRS’s FA Score: 2 green, 3 red.
  • RXRX’s FA Score: 1 green, 4 red.
According to our system of comparison, CHRS is a better buy in the long-term than RXRX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CHRS’s TA Score shows that 4 TA indicator(s) are bullish while RXRX’s TA Score has 4 bullish TA indicator(s).

  • CHRS’s TA Score: 4 bullish, 5 bearish.
  • RXRX’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, CHRS is a better buy in the short-term than RXRX.

Price Growth

CHRS (@Biotechnology) experienced а -10.37% price change this week, while RXRX (@Biotechnology) price change was -11.68% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.17%. For the same industry, the average monthly price growth was -5.68%, and the average quarterly price growth was +64.91%.

Reported Earning Dates

CHRS is expected to report earnings on Mar 17, 2026.

RXRX is expected to report earnings on Mar 04, 2026.

Industries' Descriptions

@Biotechnology (-2.17% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RXRX($2.1B) has a higher market cap than CHRS($146M). CHRS YTD gains are higher at: -12.319 vs. RXRX (-38.462). CHRS has higher annual earnings (EBITDA): 88.2M vs. RXRX (-583.64M). RXRX has more cash in the bank: 525M vs. CHRS (238M). CHRS has less debt than RXRX: CHRS (41M) vs RXRX (88.1M). CHRS has higher revenues than RXRX: CHRS (272M) vs RXRX (64.5M).
CHRSRXRXCHRS / RXRX
Capitalization146M2.1B7%
EBITDA88.2M-583.64M-15%
Gain YTD-12.319-38.46232%
P/E Ratio2.11N/A-
Revenue272M64.5M422%
Total Cash238M525M45%
Total Debt41M88.1M47%
FUNDAMENTALS RATINGS
CHRS: Fundamental Ratings
CHRS
OUTLOOK RATING
1..100
53
VALUATION
overvalued / fair valued / undervalued
1..100
32
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
5
PRICE GROWTH RATING
1..100
53
P/E GROWTH RATING
1..100
93
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
CHRSRXRX
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
87%
Momentum
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
89%
MACD
ODDS (%)
N/A
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
87%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
86%
Advances
ODDS (%)
Bullish Trend 8 days ago
74%
Bullish Trend 24 days ago
85%
Declines
ODDS (%)
Bearish Trend 3 days ago
88%
Bearish Trend 3 days ago
89%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
88%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
85%
View a ticker or compare two or three
Interact to see
Advertisement
CHRS
Daily Signal:
Gain/Loss:
RXRX
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ECIA0.250.01
+4.71%
Encision, Inc.
ALFFF0.76N/A
N/A
Alfa S.A.B de C.V
RYSKF0.35N/A
N/A
Reysas Tasimacilik Ve Lojistik
SACQF10.06N/A
N/A
Spree Acquisition Corp. 1 Limited
ACSAF88.79-2.23
-2.45%
ACS Actividades De Construccion Y Servicios SA